ENDECE logo — New Drug Concepts

ENDECE

New Drug Concepts

Founded 2006 United States Cedarburg, United States 6 employees Total: $7.44M Biotechnology, Health and Wellness +1

General Information

Company Name ENDECE
Founded Year 2006
Location United States Cedarburg, United States
Employees 6
Industries Biotechnology, Health and Wellness, Pharmaceutical
Social

BounceWatch is an independent company data service, not affiliated with ENDECE. To contact ENDECE, visit endece.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ENDECE compare?

A PDF of ENDECE and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ENDECE soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ENDECE

ENDECE is a biotechnology and pharmaceutical company based in the United States that was founded in 2006. The company focuses on developing new drug concepts to address life-threatening conditions such as Acute Respiratory Distress Syndrome (ARDS), which has a high mortality rate due to the lack of effective therapeutic options. ENDECE has designed NDC-1308 to combat the ability of SARS-CoV-2/COVID-19 to replicate within the pulmonary system and reduce inflammation. The company received a $1.20M funding round investment on 20 July 2011 to further advance its innovative drug development efforts. Given the ongoing global healthcare challenges, ENDECE's focus on novel solutions for conditions like ARDS and the impact of COVID-19 positions it as a potentially valuable investment opportunity in the biotech and pharmaceutical industries.

Business keywords: biopharmaceutical company, drug discovery, therapeutic modalities, SARS-CoV-2, COVID-19, respiratory system, inflammation, proprietary compounds, disease treatment, multiple sclerosis, Alzheimer's disease, clinical development, biological pathways, gain of function, disease research

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Funding Round $1.20M -
20 Jul 2011
Grant $244.48K -
01 Nov 2010
Funding Round $6.00M -
01 Jan 2009

ENDECE Alternatives & Competitors

View All Alternatives
ENDECE vs

Precision therapeutics for protein misfolding disorders, including Alzheimer's, ALS and Parkinson’s...

22 employees
Biotechnology, Health Care
ENDECE vs

Advancing therapeutic innovation in human cell signaling for inflammation, fibrosis, and CNS disease...

Series C
Biotechnology, Health Care
ENDECE vs

Fighting COVID-19 with fully human neutralizing antibodies

Corporate Round
7 employees
Biotechnology, Health and Wellness

FAQ About ENDECE

New Drug Concepts
ENDECE was founded in 2006.
ENDECE is headquartered in Cedarburg, United States.
ENDECE operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on biopharmaceutical company, drug discovery, therapeutic modalities and SARS-CoV-2.
ENDECE has approximately 6 employees.
ENDECE has completed 3 funding rounds, raising a total of $7.44M.
Top alternatives and competitors to ENDECE include ProMIS™ Neurosciences, Inc., Complexa, CORAT Therapeutics GmbH, vTv Therapeutics, AlphaMol Science Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ENDECE and ProMIS™ Neurosciences, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ENDECE, https://bouncewatch.com/company/endece, updated 14 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes